A Phase 1/2 interventional study of AZD9550 and placebo in Overweight and Obesity, sponsored by AstraZeneca. Active, not recruiting at 15 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Obesity by AstraZeneca — 8 open to participants now, 12 under way, 5 of them phase 3. Obesity · AstraZeneca.
Among the 52 studies in Obesity by AstraZeneca, this one is the 19th largest by enrollment of the 50 interventional ones that give a count, is one of 2 that started in 2023, is the only one in phase 1/2, reaches primary completion later than 2 of the 11 other live ones, and was the 28th registered.
11,547 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →8 of the 52 studies in Obesity by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Brazil and 8 more countries
Ages 18+
AstraZeneca · Sites in China, Hong Kong, Malaysia and 2 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 13 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 13 more countries
Ages 18+
AstraZeneca · Sites in United States
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 19 · Phase 3 6 · Phase 4 1
First in 2004; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 166 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 87 across the 50 interventional studies, 4,288 across the 2 observational. Of the 40 that completed or were terminated, 9 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
6 of the studies in Obesity by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07723833AstraZenecaA Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants | 2026-11-18 |
| NCT07534592AstraZenecaA Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants | 2027-01-25 |
| NCT06151964AstraZenecaA Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight | 2027-01-29 |
| NCT07511205AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity. | 2027-04-09 |
| NCT07911514AstraZenecaA Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234 | 2027-05-04 |
Add all 6 to your calendar (.ics) → With an account.
Among the 52 studies in Obesity by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
AZD9550, previously being developed for the treatment NASH, is a dual GCG and GLP-1 receptor agonist. AZD9550 is now being developed in combination with AZD6234, a SARA, for the treatment of overweight and obesity and its associated co-morbidities. Co-administration of AZD9550 and AZD6234 is currently being evaluated in participants living with obesity and overweight without T2DM in an ongoing Phase 2b study.
The purpose of this study is to investigate the safety, tolerability, and effects of increasing doses of AZD9550 monotherapy in overweight and obese participants aged 18 through 65 years living with or without T2DM, and to investigate how AZD9550 is absorbed, distributed, and eliminated from the body (Parts A-D).
In addition, the study will investigate the safety and tolerability of co-administration of AZD9550 and AZD6234 in participants living with T2DM with obesity or overweight aged 18 through 75 years (Part E), and safety and tolerability for different titration regimens for AZD9550 in participants living with obesity, but without T2DM, aged 18 through 75 years (Part F).
This Phase I/II, randomised, single-blind, placebo-controlled, MAD study will assess the safety and tolerability of AZD9550 monotherapy and co-administration of AZD9550 and AZD6234 and will characterise the PK and PD of AZD9550 monotherapy and co-administration of AZD9550 and AZD6234 following SC administration to overweight and obese participants living with or without T2DM. Inclusion of participants receiving placebo is appropriate for benchmarking the safety and tolerability of AZD9550 and co-administration of AZD9550 and AZD6234. A randomised and single-blind study design has been chosen to minimise bias and includes a placebo to facilitate identification of effects related to the administration of the study intervention rather than the study procedures or situation.
11,547 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's enrollment of 166 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Parts A, B, C only: Participants with or without T2DM. If participants have a diagnosis of T2DM, the glucose control managed with diabetes diet and in addition to metformin treatment no more than two treatment options (with a stable dose 3 months prior to screening).
Part D only: Participants who are diagnosed with T2DM, have inadequate glycaemic control with diet and exercise. Participants who are prescribed an oral anti-diabetic agent such as metformin, a DPP IV inhibitor, sulphonylurea, glinides, alphaglucosidase inhibitors, and an SGLT2 inhibitor may be eligible to enter the study following a of 4-weeks or 5-half lives (whichever is longer) washout period.
Part E only: Participants are eligible to be included in the Part E only if they meet all of the following criteria at screening:
Participants with a screening value within the target range of
Exclusion Criteria:
At screening blood tests, any of the following:
Abnormal vital signs, after 10 minutes of supine rest, defined as any of the following:
Use of any of the following medicinal products:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Multiple repeat doses of AZD9550 given as 4 once weekly SC doses for 4 weeks to 2 sequential cohorts in overweight/obese participants with or without T2DM, evaluating 2 low dose levels of AZD9550
Drug: AZD9550
Once weekly up-titration over 5 doses of AZD9550 in overweight/obese participants with or without T2DM
Drug: AZD9550
Bi-weekly/monthly up-titration of AZD9550 for 24 weeks in overweight/obese participants with or without T2DM.
Drug: AZD9550
Bi-weekly/monthly up-titration of AZD9550 for 24 weeks in overweight/obese Japanese participants with T2DM.
Drug: AZD9550
Multiple repeat doses of placebo given as 4 once weekly SC doses for 4 weeks to 2 sequential cohorts in overweight/obese participants with or without T2DM, evaluating 2 low dose levels of AZD9550
Drug: placebo
Once weekly administration of placebo over 5 doses, volume matched to the active treatment being up-titrated, in overweight/obese participants with or without T2DM
Drug: placebo
Bi-weekly/monthly administration of placebo - volume matched to the active treatment being up-titrated - for 24 weeks in overweight/obese participants with or without T2DM.
Drug: placebo
Bi-weekly/monthly administration of placebo - volume matched to the active treatment being up-titrated - 24 weeks in overweight/obese Japanese participants with T2DM.
Drug: placebo
Bi-weekly/monthly up-titration of AZD9550 and AZD6234 for 24 weeks in overweight/obese participants with T2DM.
Drug: AZD9550 and AZD6234
Bi-weekly/monthly administration of placebo - volume matched to the active treatments being up-titrated - 24 weeks in overweight/obese participants with T2DM.
Drug: placebo
Bi-weekly/monthly up-titration of AZD9550 for 28 weeks in obese participants without T2DM.
Drug: AZD9550
Bi-weekly/monthly administration of placebo - volume matched to the active treatment - 28 weeks in obese participants without T2DM.
Drug: placebo
Part A: A constant dose Part B: Doses of AZD9550 that increase each week Part C: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks Part D: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks Part F: Doses of AZD9550 that increase every 4 weeks or every 2 weeks and then every 4 weeks
Matching administration volumes for SC injection. For Part E placebo two injections of two different placebos.
Part E: Doses of AZD9550 and AZD6234 that increase every 2 weeks, then every 4 weeks
Number and percentage of participants with any AE, SAEs, AEs leading to discontinuation of study intervention, AEs with outcome of death, and AEs leading to withdrawal from study.
Applicable for Parts A, B, C, D, E, F.
Time frame: Day - 35 to Day 261
Number and percentage of participants with clinically significant changes from baseline in Vital Sign Parameters.
Applicable for Parts A, B, C, D, E, F.
Time frame: Day - 35 to Day 261
Number and percentage of participants with clinically significant changes in ECG parameters.
Applicable for Parts A, B, C, D, E, F.
Time frame: Day - 35 to Day 261
Number and percentage of participants with clinically significant changes from baseline in Clinical Laboratory Parameters
Applicable for Parts A, B, C, D, E, F.
Time frame: Day - 35 to Day 261
Area Under Concentration-Time Curve of AZD9550 following repeat weekly SC doses
* AUC from 0 to the time of the last measured concentration (AUClast) at first dose and last dose * AUC over a dosing interval (AUCtau) at first dose and last dose. Applicable for Part A.
Time frame: Day 1 to Day 65
Maximum observed concentration of AZD9550 following repeat weekly SC doses
• Cmax at first dose and last dose Applicable for Part A.
Time frame: Day 1 to Day 65
Half life associated with terminal phase elimination rate constant of AZD9550 following repeat weekly SC doses
• t1/2λz at first dose and last dose Applicable for Part A.
Time frame: Day 1 to Day 65
Time to maximum observed concentration of AZD9550 following repeat weekly SC doses
• tmax at first dose and last dose Applicable for Part A.
Time frame: Day 1 to Day 65
Apparent oral clearance of AZD9550 following repeat weekly SC doses
• CL/F at first dose and last dose Applicable for Part A.
Time frame: Day 1 to Day 65
Apparent volume of distribution of AZD9550 following repeat weekly SC doses
• Vz/F at first dose and last dose Applicable for Part A.
Time frame: Day 1 to Day 65
Ratio for AUC of AZD9550 following repeat weekly SC doses
• Rac AUCtau at last dose Applicable for Part A.
Time frame: Day 1 to Day 65
Ratio for Cmax of AZD9550 following repeat weekly SC doses
• Rac Cmax at last dose Applicable for Part A.
Time frame: Day 1 to Day 65
PD effect of AZD9550 on fasting glucose compared to placebo
• Absolute change in fasting glucose Applicable for Part A.
Time frame: From baseline to Week 4
PD effect of AZD9550 on fasting lipid profile compared to placebo
• Absolute and percentage change in total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides, and BHB Applicable for Part A.
Time frame: From baseline to Week 4
Absolute and percentage change in body weight from baseline
Applicable for Part A.
Time frame: From baseline to Week 4
Incidence of anti-AZD9550 antibodies
• Incidence of ADA to AZD9550 Applicable for Part A.
Time frame: From Day 1 to Day 65
Absolute change in percentage body fat from baseline
Applicable for Part A.
Time frame: From baseline to Week 4
PD effect of AZD9550 on fasting glucose compared to placebo
• Absolute change in fasting glucose Applicable for Part B.
Time frame: From baseline to Week 5
PD effect of AZD9550 on fasting lipid profile compared to placebo
• Absolute and percentage change in total cholesterol, high-density lipoprotein, low-density lipoprotein, triglyceride, and BHB Applicable for Part B.
Time frame: From baseline to Week 5
Effect of AZD9550 on hepatic fat fraction versus placebo at Week 5
* Change in hepatic fat fraction as measured by MRI-PDFF * Percent change in hepatic fat fraction as measured by MRI-PDFF Applicable for Part B.
Time frame: From baseline to Week 5
PD effect of AZD9550 on glucose metabolism following an MMTT compared to placebo
* Percent change in glucose AUC(0-4h) measured by MMTT * Percent change in insulin AUC(0-4h) measured by MMTT * Percent change in c-peptide AUC(0-4h) measured by MMTT Applicable for Part B.
Time frame: From baseline to Week 5
Area Under concentration-time Curve of AZD9550 following repeat weekly SC doses
* AUC from 0 to the time of the last measured concentration (AUClast) at the last dose * AUC over a dosing interval (AUCtau) at first dose and last dose Applicable for Part B.
Time frame: Day 1 to Day 72
Incidence of anti-AZD9550 antibodies
• Incidence of ADA to AZD9550 Applicable for Part B.
Time frame: Day 1 to Day 72
PD effect of AZD9550 on fasting glucose compared to placebo
• Absolute change in fasting glucose Applicable for Parts C and D.
Time frame: From baseline to Week 24
PD effect of AZD9550 on fasting lipid profile compared to placebo
• Absolute and percentage change in total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides, and BHB Applicable for Parts C and D.
Time frame: From baseline to Week 24
The effect of AZD9550 on hepatic fat fraction versus placebo after 13 and 24 weeks of treatment
* Change in hepatic fat fraction as measured by MRI-PDFF * Percent change in hepatic fat fraction as measured by MRI-PDFF Applicable for Part C.
Time frame: From baseline to Weeks 13 and 24
Effects of AZD9550 compared to placebo on body weight
* Change in body weight * Percent change in body weight • Proportion of participants achieving ≥ 5% body weight loss • Proportion of participants achieving ≥ 10% body weight loss * Absolute change in percentage body fat Applicable for Parts C and D.
Time frame: From baseline to Week 24
Change in daily (24 hours) average glucose levels as measured by CGM
Applicable for Parts C and D.
Time frame: From baseline to Day 176
Change in fasting hepatic glycogen concentration adjusted for liver volume as measured by MRS
Applicable for Part C.
Time frame: From baseline to Weeks 13 and 24
Area Under concentration-time Curve of AZD9550 following repeat weekly SC doses
* AUC from 0 to the time of the last measured concentration (AUClast) at the first doses of each dose level and the last dose of MTD * AUC over a dosing interval (AUCtau) at the first doses of each dose level and the last dose of MTD Applicable for Parts C and D.
Time frame: Day 1 to Day 169
Incidence of anti-AZD9550 antibodies
• Incidence of ADA to AZD9550 Applicable for Parts C and D.
Time frame: Day 1 to Day 205
Change in daily (24 hours) average glucose levels as measured by CGM
Applicable for Part A (excluding during 14 days post last dose). Applicable for Part B (excluding from baseline to Week 6 and during 14 days post last dose). Applicable for Parts C and D.
Time frame: From baseline to Weeks 1, 2, 3, 4, 5, and 6, and during 14 days post last dose
Change in 7-day average glucose levels as measured by CGM
Applicable for Part A (excluding during 14 days post last dose). Applicable for Part B (excluding from baseline to Week 6 and during 14 days post last dose). Applicable for Parts C and D.
Time frame: From baseline to Weeks 1, 2, 3, 4, 5, and 6 and during 14 days post last dose
Change in coefficient of variation of glucose levels as measured by CGM over 7 days
Applicable for Part A (excluding during 14 days post last dose). Applicable for Part B (excluding from baseline to Week 6 and during 14 days post last dose). Applicable for Parts C and D.
Time frame: From baseline to Weeks 1, 2, 3, 4, 5, and 6, and during 14 days post last dose
Change in percentage time spent in hyperglycaemia (> 140 mg/dL), normoglycaemia (70 -140 mg/dL), and clinically significant hypoglycaemia (< 54 mg/dL) as measured by CGM over 24 hours
Applicable for Part A (excluding during 14 days post last dose). Applicable for Part B (excluding from baseline to Week 6 and during 14 days post last dose). Applicable for Parts C and D.
Time frame: From baseline to Weeks 1, 2, 3, 4, 5, and 6, and during 14 days post last dose
Change in percentage time spent in hyperglycaemia (> 140 mg/dL), normoglycaemia (70 -140 mg/dL), and clinically significant hypoglycaemia (< 54 mg/dL) as measured by CGM over 7 days
Applicable for Part A (excluding during 14 days post last dose). Applicable for Part B (excluding from baseline to Week 6 and during 14 days post last dose). Applicable for Parts C and D.
Time frame: From baseline to Weeks 1, 2, 3, 4, 5, and 6, and during 14 days post last dose
Change in fasting hepatic glycogen concentration adjusted for liver volume as measured by MRS
Applicable for Part B.
Time frame: From baseline to Week 5
Percentage change in fasting hepatic glycogen concentration adjusted for liver volume as measured by MRS
Applicable for Part B.
Time frame: From baseline to Week 5
Change in fasting hepatic glycogen concentration unadjusted for liver volume as measured by MRS
Applicable for Part B.
Time frame: From baseline to Week 5
Percentage change in fasting hepatic glycogen concentration unadjusted for liver volume as measured by MRS
Applicable for Part B.
Time frame: From baseline to Week 5
Change in liver volume as measured by MRI
Applicable for Part B.
Time frame: From baseline to Week 5
Absolute change in body weight
Applicable for Part B.
Time frame: From baseline to Week 5
Percent change in body weight
Applicable for Part B.
Time frame: From baseline to Week 5
Proportion of participants achieving ≥ 5% body weight loss
Applicable for Part B.
Time frame: From baseline to Week 5
Proportion of participants achieving ≥ 10% body weight loss
Applicable for Part B.
Time frame: From baseline to Week 5
Change in 7-day average glucose levels as measured by CGM
Applicable for Parts C and D.
Time frame: From baseline to Day 176
Change in coefficient of variation of glucose levels as measured by CGM over 7 days
Applicable for Parts C and D.
Time frame: From baseline to Day 176 and during 14 days post last dose
Change in percentage time spent in hyperglycaemia (> 140 mg/dL), normoglycaemia (70 -140 mg/dL), and clinically significant hypoglycaemia (< 54 mg/dL) as measured by CGM over 24 hours
Applicable for Parts C and D.
Time frame: From baseline to Day 176
Change in percentage time spent in hyperglycaemia (> 140 mg/dL), normoglycaemia (70 -140 mg/dL), and clinically significant hypoglycaemia (< 54 mg/dL) as measured by CGM over 7 days
Applicable for Parts C and D.
Time frame: From baseline to Day 176 and during 14 days post last dose
Percentage change in fasting hepatic glycogen concentration adjusted for liver volume as measured by MRS
Applicable for Part C.
Time frame: From baseline to Weeks 13 and 24
Change in fasting hepatic glycogen concentration unadjusted for liver volume as measured by MRS
Applicable for Part C.
Time frame: From baseline to Weeks 13 and 24
Percentage change in fasting hepatic glycogen concentration unadjusted for liver volume as measured by MRS
Applicable for Part C.
Time frame: From baseline to Weeks 13 and 24
Change in liver volume, visceral and SC fat as measured by MRI
Applicable for Part C.
Time frame: From baseline to Weeks 13 and 24
Anti-AZD9550 antibody titre among participants with positive serum antibodies to AZD9550
• Titre of ADA to AZD9550 Applicable for Part A.
Time frame: From Day 1 to 65
Maximum observed concentration of AZD9550 following repeat weekly SC doses
• Cmax at the last dose Applicable for Part B.
Time frame: Day to Day 72
Half life associated with terminal phase elimination rate constant of AZD9550 following repeat weekly SC doses
• t1/2λz at the last dose Applicable for Part B.
Time frame: Day 1 to Day 72
Time to maximum observed concentration of AZD9550 following repeat weekly SC doses
• tmax at the last dose Applicable for Part B.
Time frame: Day 1 to Day 72
Apparent oral clearance of AZD9550 following repeat weekly SC doses
• CL/F at the last dose Applicable for Part B.
Time frame: Day 1 to day 72
Apparent volume of distribution of AZD9550 following repeat weekly SC doses
• Vz/F at the last dose Applicable for Part B.
Time frame: Day 1 to Day 72
Anti-AZD9550 antibody titre among participants with positive serum antibodies to AZD9550
• Titre of ADA to AZD9550 Applicable for Part B.
Time frame: Day 1 to Day 72
Maximum observed concentration of AZD9550 following repeat weekly SC doses
• Cmax at the first doses of each dose level and the last dose of MTD Applicable for Parts C and D.
Time frame: Day 1 to Day 169
Half life associated with terminal phase elimination rate constant of AZD9550 following repeat weekly SC doses
• t1/2λz at the first doses of each dose level and the last dose of MTD Applicable for Parts C and D.
Time frame: Day 1 to Day 169
Time to maximum observed concentration of AZD9550 following repeat weekly SC doses
• tmax at the first doses of each dose level and the last dose of MTD Applicable for Parts C and D.
Time frame: Day 1 to Day 169
Apparent oral clearance of AZD9550 following repeat weekly SC doses
• CL/F at the first doses of each dose level and the last dose of MTD Applicable for Parts C and D.
Time frame: Day 1 to Day 169
Apparent volume of distribution of AZD9550 following repeat weekly SC doses
• Vz/F at the first doses of each dose level and the last dose of MTD Applicable for Parts C and D.
Time frame: Day 1 to day 169
Anti-AZD9550 antibody titre among participants with positive serum antibodies to AZD9550
• Titre of ADA to AZD9550 Applicable for Parts C and D.
Time frame: Day 1 to Day 205
Change in visceral and subcutaneous fat as measured by MRI
Applicable for Part B.
Time frame: From baseline to week 5
PD effect of AZD9550 on glucose metabolism compared to placebo
• Percent change in fasting glucose, fasting insulin, fasting c-peptide, and HbA1c Applicable for Part A.
Time frame: From baseline to Week 4
PD effect of AZD9550 on glucose metabolism compared to placebo
• Percent change in fasting glucose, fasting insulin, fasting c-peptide, and HbA1c Applicable for Part B.
Time frame: From baseline to Week 5
PD effect of AZD9550 on glucose metabolism compared to placebo
• Percent change in fasting glucose, fasting insulin, fasting c-peptide, and HbA1c Applicable for Parts C and D.
Time frame: From baseline to Week 24
PD effect of AZD9550 on fasting insulin compared to placebo
• Absolute change in fasting insulin Applicable for Part A.
Time frame: From baseline to Week 4
PD effect of AZD9550 on fasting c-peptide compared to placebo
• Absolute change in fasting c-peptide Applicable for Part A.
Time frame: From baseline to Week 4
PD effect of AZD9550 on fasting insulin compared to placebo
• Absolute change in fasting insulin Applicable for Parts C and D.
Time frame: From baseline to Week 24
PD effect of AZD9550 on fasting c-peptide compared to placebo
• Absolute change in fasting c-peptide Applicable for Parts C and D.
Time frame: From baseline to Week 24
PD effect of AZD9550 on fasting insulin compared to placebo
• Absolute change in fasting insulin Applicable for Part B.
Time frame: From baseline to Week 5
PD effect of AZD9550 on fasting c-peptide compared to placebo
• Absolute change in fasting c-peptide Applicable for Part B.
Time frame: From baseline to Week 5
Absolute change in percentage body fat
Applicable for Part B.
Time frame: From baseline to Week 5
PD effect of AZD9550 on glucose metabolism following an MMTT compared to placebo
* Percent change in glucose AUC(0-4h) measured by MMTT * Percent change in insulin AUC(0-4h) measured by MMTT * Percent change in c-peptide AUC(0-4h) measured by MMTT * Absolute change in fasting glucose, fasting insulin, and fasting c-peptide * Percent change in fasting glucose, fasting insulin, and fasting c-peptide Applicable for Part C.
Time frame: From baseline to Week 13 and Week 24
PD effect of AZD9550 on HbA1c compared to placebo
• Absolute change in HbA1c Applicable for Part A.
Time frame: From baseline to Week 4
PD effect of AZD9550 on HbA1c compared to placebo
• Absolute change in HbA1c Applicable for Part B.
Time frame: From baseline to Week 5
PD effect of AZD9550 on HbA1c compared to placebo
• Absolute change in HbA1c Applicable for Parts C and D.
Time frame: From baseline to Week 24
Prevalence, incidence, and titres of ADAs to AZD9550 following co administration of AZD9550 and AZD6234
• To assess the immunogenicity profile of AZD9550 following co administration with AZD6234. Applicable for Part E.
Time frame: After 24 weeks
Incidence and titre of ADA to AZD9550
• To evaluate the immunogenicity profile of AZD9550. Applicable for Part F.
Time frame: Day 1 to Day 261
Change and percent change in body weight
• To assess the effects of AZD9550 compared to placebo on body weight Applicable for Part F.
Time frame: From baseline to Week 29
Proportion of participants achieving ≥ 5% body weight loss
• To assess the effects of AZD9550 compared to placebo on body weight Applicable for Part F.
Time frame: From baselines to Week 29
Proportion of participants achieving ≥ 10% body weight loss
• To assess the effects of AZD9550 compared to placebo on body weight Applicable for Part F.
Time frame: From baseline to Week 29
Prevalence, incidence, and titres of ADAs to AZD6234 following co administration of AZD9550 and AZD6234
• To assess the immunogenicity profile of AZD6234 following co administration with AZD9550. Applicable for Part E.
Time frame: After 24 weeks
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Sep 2023 (actual). Primary completion is estimated for Jan 2027, 40 months after the start.
Of 62 phase 1/2 interventional studies under Obesity, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's planned 40 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AZD9550